|
WO2020176552A1
|
|
Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
|
|
WO2020168300A1
|
|
Modified natural killer (nk) cells for immunotherapy
|
|
WO2020160412A1
|
|
Crispr/cas-related methods and compositions targeting virus genomes
|
|
WO2020113112A1
|
|
Systems and methods for the treatment of hemoglobinopathies
|
|
AU2019314208A1
|
|
Compositions and methods for treating CEP290-associated disease
|
|
AU2019291918A1
|
|
Synthetic guide molecules, compositions and methods relating thereto
|
|
CA3093701A1
|
|
Systems and methods for the treatment of hemoglobinopathies
|
|
BR112020018364A2
|
|
SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
CA3093289A1
|
|
Systems and methods for the treatment of hemoglobinopathies
|
|
EP3746556A1
|
|
Crispr/cas-related methods and compositions for treating herpes simplex virus (hsv) related keratitis
|
|
WO2019152519A1
|
|
Systems and methods for modulating chromosomal rearrangements
|
|
AU2018383712A1
|
|
Cpf1-related methods and compositions for gene editing
|
|
WO2019094518A1
|
|
Targeted integration systems and methods for the treatment of hemoglobinopathies
|
|
KR20200079312A
|
|
CRISPR-CAS9 editing method, composition and components of CBLB in T cells for immunotherapy
|
|
WO2019089884A2
|
|
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
EP3701028A1
|
|
Systems and methods for treating hyper-igm syndrome
|
|
US2019201550A1
|
|
Compositions and methods for treating cep290-associated disease
|
|
US2020165636A1
|
|
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
AU2018279829A1
|
|
Engineered Cas9 nucleases
|
|
EP3622070A2
|
|
Crispr/rna-guided nuclease systems and methods
|
